https://www.selleckchem.com/pr....oducts/gilteritinib-
October 2006. ClinicalTrials.gov NCT00577954. Registered on October 2006.The objective of this study was to analyze erythromycin and clindamycin resistance patterns among different MRSA lineages in China. Antimicrobial susceptibility testing, resistance determinant screening, plasmid electroporation and sequence comparisons were performed. High rates of clindamycin (92.5%, 270/292) and erythromycin (92.8%, 271/292) resistance were observed. Additionally, 88.2% (60/68) of the ST59 MRSA isolates and 78.9% (15/19) of the ST239
Aimer
Commentaire
Partagez
